首页> 外文期刊>The clinical journal of pain >Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain
【24h】

Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain

机译:遵守综合报告审判标准(共配)指南,用于报告医疗大麻和大麻药物的慢性非癌症疼痛的试验中的安全结果

获取原文
获取原文并翻译 | 示例
           

摘要

Supplemental Digital Content is available in the text. Objective: Current treatments for chronic pain have limited effectiveness and tolerability. With growing interest in the potential of cannabinoids, there is a need to inform risk-benefit considerations. Thus, this focused systematic review assesses the quality of safety assessment and reporting in chronic noncancer pain cannabinoid trials. Methods: The protocol for this review has been published, and, registered in PROSPERO. We searched MEDLINE, Embase, The Cochrane Library, Scopus, and PsychINFO for double-blind, placebo-controlled, randomized controlled trials of cannabinoids for chronic pain, with a primary outcome related to pain. The primary review outcome is adherence to the 2004 Consolidated Standards of Reporting Trials (CONSORT) Harms extension. Secondary outcomes included type, reporting method, frequency and severity of adverse events (AEs), trial participant withdrawals, and reasons for withdrawals. Results: In total, 43 studies (4436 participants) were included. Type of cannabinoid (number of studies) included nabiximols (12), dronabinol (8), nabilone (7), oral cannabis extract preparations (5), smoked tetrahydrocannabinol (5), vaporized tetrahydrocannabinol (3), novel synthetic cannabinoids (2), sublingual cannabis extract preparations (1). The median CONSORT score was 7. On average, 3 to 4 recommendations of the CONSORT guidelines were not being met in trials. Seventeen trials did not provide their method of AE assessment, 14 trials did not report on serious AEs and, 7 trials provided no quantitative data about AEs. Discussion: Better harms assessment and reporting are needed in chronic pain cannabinoid trials. Improvements may be achieved through: expanded education/knowledge translation increased research regulation by ethics boards, funding agencies and journals, and greater emphasis on safety assessment and reporting throughout research training.
机译:文本中提供了补充数字内容。目的:目前对慢性疼痛的治疗有限,有效性和耐受性。随着对大麻素潜力的兴趣日益增长,需要提供风险效益的考虑因素。因此,这种重点的系统评价评估了慢性非癌症疼痛大麻试验的安全评估和报告的质量。方法:该评论的议定书已发布,并在Prospero注册。我们搜索了Medline,Embase,Cochrane图书馆,Scopus和Psychinfo进行双盲,安慰剂对照,随机对照试验,用于慢性疼痛,主要结果与疼痛有关。初级审查结果是遵守2004年综合报告审判标准(共配)危害延期。次要结果包括型号,报告方法,不良事件的频率和严重程度(AES),试验参与者提款和提款的原因。结果:共有43项研究(4436名参与者)。大麻素(研究数量)包括Nabiximols(12),Dronabol(8),Nabilone(7),口服大麻提取物制剂(5),烟熏四氢尼醇(5),蒸发的四氢呋喃(3),新型合成大麻素(2) ,舌下大麻提取物制剂(1)。中位数分数为7.平均而言,在审判中没有满足3至4个联盟指南的建议。十七项试验没有提供他们的AE评估方法,14项试验没有报告严重的AES,7项试验没有提供关于AES的数量数据。讨论:在慢性疼痛大麻素试验中需要更好的危害评估和报告。通过:扩展教育/知识翻译可以实现改进:伦理委员会,资金机构和期刊的研究监管,并更加重视在研究培训的过程中的安全评估和报告。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号